About Contact Us Careers
Sign In

Rituximab Market Size & Share, by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); Application (Blood Cancer, Rheumatoid Arthritis, Wegener Granulomatosis) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3315
  • Published Date: Sep 01, 2023
  • Report Format: PDF, PPT

Companies Dominating the Rituximab Landscape

top-features-companies
    • Amgen Inc
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Henlius Biotech, Inc.
    • Nordic Nanovector ASA
    • Biocon Biologics Ltd
    • Pfizer Inc.
    • Chugai Pharmaceuticals
    • Zenyaku Kogyo Co. Ltd,
    • SymBio Pharmaceuticals
    • Daiichi Sankyo
    • Kyowa Kirin Co. Ltd
Browse Key Market Insights with Data Illustration:

In the News

  • Nordic Nanovector ASA announced the successful outcomes of the Archer-1 phase B trial for treating second-line follicular lymphoma (2L FL), investing Betalutin (177Lu lilotomab satetraxetan) in combination with rituximab (RTX).
  •  Biocon Biologics Ltd has signed an agreement with the Clinton Health Initiative (CHAI) to expand access to lifesaving cancer biosimilars in over 30 countries in Africa and Asia as a part of the Cancer Access Partnership (CAP).

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 3315
  • Published Date: Sep 01, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing demand for monoclonal antibodies, increasing collaborations for the development of new products and investment in healthcare sector.

The market size of rituximab is anticipated to attain a CAGR of 16% over the forecast period, i.e., 2023 – 2035.

The major players in the market are Amgen Inc, Henlius Biotech, Inc., Nordic Nanovector ASA, Biocon Biologics Ltd., Pfizer Inc., Chugai Pharmaceuticals, Zenyaku Kogyo Co. Ltd, SymBio Pharmaceuticals, Daiichi Sankyo, Kyowa Kirin Co. Ltd, and others.

The blood cancer segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying